The Duke Precision Medicine Program aims to bring proven precision medicine technologies from the basic science portfolio to the clinical settings through both research and clinical programs. Precision medicine technologies are broad-based and include specific tools such as wearables or our family history risk assessment platform, as well as predictive models that incorporate multiple modalities using state of the art scientific principles like machine learning. Housed in the Division of General Internal Medicine in the Duke Department of Medicine, our team is particularly interested in incorporating 'omic technologies, such as genomics, transcriptomics, and epigenomics, into clinical environments to enhance patient care and has broad based expertise in health services research, implementation science, and complex data. 

"Precision Medicine is the future of medicine and we are excited to be on the forefront of research, advancements, and discoveries." - Lori Orlando, Director of the Duke Precision Medicine Program

Lori Orlando

Lori Orlando, MD, MHS, MMCI
Director of the Duke Precision Medicine Program

Learn more about our work

The pace of precision medicine is rapidly accelerating and it’s potential to improve individual and population health is as well. However, precision medicine’s unique complexities make it difficult to incorporate into our existing healthcare infrastructure and processes.

Our goal is to identify and address these challenges so that patients and providers have the data, tools, and resources they need to optimize health.

Research

Our team is dedicated to advancing research in precision medicine through ongoing studies through trial networks housed at Duke University.

  • GUARDD-US: Genetic testing to understand renal disease disparities across the US through the IGNITE Pragmatic Clinical Trials Network

Health Care

Our team has developed and implemented various initiatives, programs, and tools, to bring precision medicine into the hands of providers, including both clinicians and pharmacists.

  • PHASER: Pharmacogenomics Testing for Veterans program (PHASER), brings pharmacogenomic testing to Veterans across the country receiving care at a VA. Led by Founding Director, Deepak Voora, PHASER uses this type of testing to optimize prescriptions using genetic data from patients to reduce adverse side effects and improve medication outcomes. 
  • MeTree: Developed by the Duke Precision Medicine Program, MeTree is a web-based, patient-facing risk assessment tool that collects personal health information and family health history.

Education & Training

Educating the next generation of researchers and health care providers in genomics and precision medicine is part of the fabric of our values. We are committed to providing extraordinary mentorship and educational experiences to future genomics researchers, educators, and clinicians.

News & Recognition

See what's happening at the Duke Precision Medicine Program:


Lori Presentation

Orlando speaks at WSU College of Medicine Genomics & Adoption Symposium

Lori Orlando, MD, MHS, MMCI, director of the precision medicine program in the Center for Applied Genomics & Precision Medicine at Duke University School of Medicine, spoke at the Washington State University Elson S. Floyd College of Medicine 2021 Genomics & Adoption Symposium today.
Ginsburg

Ginsburg named Chief Medical & Scientific Officer, NIH All of Us Research Program

Geoffrey Ginsburg, MD, PhD, a professor of Medicine (Cardiology), Pathology, Biostatistics and Bioinformatics, and Biomedical Engineering, and a professor in School of Nursing, will leave Duke to assume the role of Chief Medical and Scientific Officer for the National Institutes of Health (NIH) All of Us Research Program, effective January 2022. In this role, Dr. Ginsburg will help direct the national scientific research agenda to improve health and accelerate research using precision medicine.
British Journal of Clinical Pharmacology

CAGPM’s Deepak Voora, Rachel Myers and Geoffrey Ginsburg explore aspirin effects on platelet gene expression

A new study by Duke researchers, including Duke Center for Applied Genomics members Deepak Voora, MD, Geoffrey Ginsburg, MD, PhD, and first author, Rachel Meyers, PhD, explores why aspirin may not work as well as expected against stroke and heart attack and to better understand any differences between low- and high-dose aspirin – one of the most commonly used medications worldwide.
Journal of Personalized Medicine

Collaboration with Duke-NUS led by Dr. Ryanne Wu explores implementation and experience of FHH tool among breast cancer patients in Singapore

On the heels of October highlighting breast cancer awareness and entering November when National Family Health History month is recognized, Dr. Ryanne Wu, MD, MHS, Associate Professor of Medicine and faculty at the Duke Center for Applied Genomics & Precision Medicine (CAGPM), recently completed a study on the “Development and Clinical Implementation Pilot of an Oncology-specific Risk Assessment tool in Singapore”, funded by the Duke/Duke-National University of Singapore (NUS) Research Collaboration funding mechanism.